Thousand Oaks, CA, United States of America

Markian Myroslaw Stec

This inventor holds 23 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Amgen Inc.. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Markian Myroslaw Stec. Retrieved from https://idiyas.com/inventor/markian-myroslaw-stec

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 5)

% Patents Active = 60.9

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 10.9

ph-index = 8

Forward Citations = 201(Granted Patents)

Location History:

Filmore, CA (US) (2006)
Fillmore, CA (US) (2006 - 2009)
Moorpark, CA (US) (2010 - 2020)
Thousand Oaks, CA (US) (2013 - 2022)

Company Filing History:

23 out of 2,074

Amgen Inc.

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Mcl-1 Inhibitors

Vanilloid Receptor Ligands

Beta-Secretase Inhibitors

Glucokinase Regulatory Protein

Imidazopyridazine

Fused Heterocyclic Derivatives

Nitrogen-Containing Compounds

Substituted Alkylamine Derivatives

Cancer Treatment

Diabetes Treatment

Piperazinyl Amides

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741977 - Methylation of Mcl-1 compounds (2026-09-22),

2. 12643913 - Mcl-1 inhibitor formulations (2026-06-02),

3. 11224601 - Compounds that inhibits MCL-1 protein (2022-01-18),

4. 10821115 - Compounds that inhibit Mcl-1 protein (2020-11-03),

5. 10632128 - Compounds that inhibit Mcl-1 protein (2020-04-28),

6. 10500213 - Compounds that inhibit Mcl-1 protein (2019-12-10),

7. 10300075 - Compounds that inhibit MCL-1 protein (2019-05-28),

8. 9550762 - Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-01-24),

9. 9066954 - Fused heterocyclic derivatives and methods of use (2015-06-30),

10. 8642624 - Substituted alkylamine derivatives and methods of use (2014-02-04),

11. 8524900 - Fused heterocyclic derivatives and methods of use (2013-09-03),

12. 8431563 - Compounds that interact with glucokinase regulatory protein for the treatment of diabetes (2013-04-30),

13. 8314087 - Nitrogen-containing heterocyclyl ketones and methods of use (2012-11-20),

14. 7820665 - Imidazopyridazine inhibitors of PI3 kinase for cancer treatment (2010-10-26),

15. 7524874 - Vanilloid receptor ligands and their use in treatments (2009-04-28),

Title: The Innovative Journey of Markian Myroslaw Stec

Introduction:

Markian Myroslaw Stec, a talented inventor based in Thousand Oaks, CA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents:

Markian Myroslaw Stec holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and creativity.

Career Highlights:

Throughout his career, Markian Myroslaw Stec has worked with top research institutions and leading tech companies, where he has spearheaded projects that have revolutionized various industries. His passion for pushing the boundaries of technology is evident in the numerous successful products he has developed.

Collaborations:

Markian Myroslaw Stec is known for his collaborative spirit, having partnered with renowned inventors, engineers, and scientists to bring his ideas to life. His ability to work effectively in multidisciplinary teams has led to the creation of cutting-edge solutions that have had a lasting impact.

Conclusion:

In conclusion, Markian Myroslaw Stec's innovative spirit, coupled with his dedication to excellence, has solidified his reputation as a pioneering inventor in the tech world. His relentless pursuit of innovation continues to inspire others in the field to think outside the box and create a better future through technology.

Profile summary based on public USPTO records.